Ludivine Pont named CEO of Officina Profumo-Farmaceutica di Santa Maria Novella
Pont is a well-known figure in the luxury industry. She joins Officina Santa Maria Novella from Balenciaga, where she was Chief Marketing Officer. Her new position takes effect in September.
Pont's appointment comes 18 months after Giovanna Paoloni was named CEO of the Florence-based brand. According to her LinkedIn profile, Paoloni quit Officina Santa Maria Novella in January this year.
In a busy career, Pont has held leadership roles across several major global fashion houses, notably contributing to the international expansion of Philipp Plein. Subsequently, she joined Moncler in 2016, where she led the development of new brand platforms and innovative communication models.
In 2021, she moved to Balenciaga, where she worked closely with artistic director Demna to develop a culturally resonant strategy, expanding the brand's global resonance through a creative-led approach and digital innovation. In 2022, she was named among Forbes' Most Entrepreneurial CMOs in Marketing.
In her new role, Pont will be responsible for leading the brand's global development, building on the unique heritage and artisanal know-how of Officina Profumo-Farmaceutica di Santa Maria Novella, with the ambition to affirm its positioning as the original and timeless expression of pharmaceutical and botanical care, the brand said in a release.
'We are delighted to welcome Ludivine Pont to the Italmobiliare Group: thanks to her profound skills, international experience and strategic vision, we are certain she is the right person to contribute to the growth of the Group, giving further impetus to the global development of Officina Profumo-Farmaceutica di Santa Maria Novella, always respecting the values and peculiarities that make the company a brand without equal in the world,' said Carlo Pesenti, CEO of Italmobiliare and Chairman of Officina Profumo-Farmaceutica di Santa Maria Novella,
Added Pont: 'It is a great honor and a profound responsibility to take on the leadership of Officina Profumo-Farmaceutica di Santa Maria Novella.'
'This is a house with an extraordinary legacy, over eight centuries of botanical and pharmaceutical excellence. My goal is to carry this heritage forward and create an experience of timeless care that speaks to the senses, to beauty, and to time,' she continued.
Until September, the company will continue to be led by General Manager Giampiero Pesenti and the current management team. Thereafter, Giampiero Pesenti will continue to play a central role in the operational guidance of the company, supporting the new phase of strategic development under the leadership of Ludivine Pont.
Officina Profumo-Farmaceutica di Santa Maria Novella is currently present in over 30 countries, with a network of more than 400 points of sale. Since its acquisition in 2020, Italmobiliare has supported the company's international development and strategic transformation.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euronews
4 hours ago
- Euronews
Hunger surge strikes Middle East and Africa, UN survey shows
The ongoing burden of rising global crises has exacerbated hunger in Africa, Asia and the Middle East, UN agencies warn. According to the UN's State of Food Security and Nutrition in the World 2025 report, also known as the SOFI report, trade tensions, conflicts and climate change are the primary causes of global food inflation. The report, which gathers data from five international organisations — FAO, IFAD, UNICEF, WFP, and WHO — was drafted by IFAD, a Rome-based UN agency that provides grants and low-interest loans to fund projects in developing countries. "The situation is quite alarming, especially in Africa and in the Middle East," Álvaro Lario, president of IFAD, told Euronews. "It's a mixture between the conflicts, some of the disruption or shocks caused by economic or trade tensions and also the climate shocks. These are the three main drivers," Lario explained. Since the trade tensions of 2018, during the first Trump administration, elevated tariffs have mainly remained in place, contributing to ongoing trade tensions and influencing global agricultural trade dynamics. The figures of the survey show that the proportion of the population facing hunger in Africa surpassed 20% in 2024, affecting 307 million people, while in the Middle East an estimated 12.7% of the population, or more than 39 million people, faced hunger in 2024. Small farming activities under threat Increasingly dire living conditions for small farmers and rural populations in developing countries are catalysts for economic migration flows. "It's clear, when people do not have the ability of really having a livelihood where they are, then they are forced to migrate," Lario said. The link between migration, the ability to feed oneself, and the ability to also continue producing food is clear, he added. According to UN criteria, small-scale farmers are those who exploit less than 2 hectares of land. They produce one-third of the world's food and up to 70% of the food in Africa. The economic existence and sustainability of small-scale farmers are quintessential to food supply and food security in developing countries. Yet, according to international standards, they all live under the poverty threshold. They represent 80% of the world's poorest population. According to the IFAD assessment, international aid to agriculture doesn't meet the needs of small-scale farmers: in fact, they receive less than 1% of climate finance, which amounts to slightly more than €4 billion per year, when they would need more than €70 billion. Long-term investment in agriculture and small-scale farmers in developing countries is crucial for addressing global hunger. "Africa imports approximately €70, 80 billion of food every year. Clearly, they could be self-sufficient and they could create a lot of those jobs in Africa," said Lario. Each year, approximately 10 million young Africans enter the job market. "There could be many jobs created in terms of not only production, but distribution, storage, marketing, exporting," Lario stated. Rising conflicts disrupt the food chain According to the Integrated Food Security Phase Classification (IPC), more than 35 million people are living in a state of emergency (IPC Phase 4), and almost 2 million have reached IPC Phase 5, which is categorised as "catastrophe". Places where the population is facing extreme degrees of food insecurity are the Palestinians living in the Gaza Strip, along with South Sudan, Sudan, Yemen and Haiti. The survey indicates that 100% of the population in the Gaza Strip faces high levels of acute food insecurity, affecting a total of 1,106,900 people, nearly twice the 576,000 recorded in 2023, the highest numbers ever estimated globally in IPC history. "The situation is quite alarming, especially in Africa and especially in the Middle East. I would say those are the two areas where we're saying the numbers continue to increase," concluded Lario.
Euronews
5 hours ago
- Euronews
EU-US trade deal leaves future of pharma tariffs uncertain
The current status of tariffs on pharmaceuticals between the EU and the US remains uncertain, despite the announcement on Sunday of a new transatlantic trade agreement. The situation is particularly sensitive given the mutual dependency in the sector: the US imports large volumes of critical pharmaceuticals from the EU, while EU-based pharmaceutical companies—especially in Ireland and Denmark—rely heavily on access to the American market. Although the new trade agreement will officially enter into force on 1 August, pharmaceuticals will not be subject to a 15% tariff which will be slapped on most goods imported from the European Union to the United States. This does not mean that there won't be tariffs at all on pharmaceuticals, as the US is still conducting an investigation into imported pharmaceuticals to assess whether they threaten US national security. For this reason, pharmaceuticals were technically excluded from yesterday's formal agreement, several EU sources confirm, as the US could not commit to any decision on tariff changes, which will only come after the conclusion of that process. However, if tariffs are introduced following the investigation, the EU expects the US—under President Trump—to honour the informal understanding reached during negotiations. This includes a cap of 15% on tariffs, which the EU considers "all-inclusive", meaning it should apply even to products still under investigation, such as pharmaceuticals and semiconductors. 'I believe that this commitment will be honoured and respected in this case as well,' said EU Trade Commissioner Maroš Šefčovič during a press briefing following the deal. So, what happens after 1 August? In the short term, nothing will change. Despite earlier reports suggesting the US would impose a 15% tariff on pharmaceuticals too in line with most EU goods, that is not expected to happen immediately. 'There will be no tariffs on pharmaceuticals this Friday,' clarified a senior EU official who participated in the negotiations with President Trump in Scotland. Most pharmaceutical products traded between the EU and the US currently benefit from a 0% tariff rate under the Most-Favoured Nation (MFN) framework. This is consistent with prior US-EU trade arrangements and World Trade Organization (WTO) commitments. As a result, EU pharmaceutical exports have faced no tariff barriers when entering the US market—a condition that remained unchanged even after Trump's so-called "Liberation Day", when he announced imposing blanket tariffs on goods. Uncertain outcome of the US investigation But tariffs on pharmaceuticals are expected to come at one point. The key uncertainty revolves around the ongoing Section 232 investigation being conducted by the Trump administration. This probe, authorised under the Trade Expansion Act of 1962, is intended to assess whether imports of pharmaceuticals (and other products as well such as semiconductors) threaten US national security. The investigation's conclusions could lead to unilateral actions by the US, including higher tariffs or import restrictions, independent of the broader trade deal struck yesterday. '[During the talks] President Trump wanted to make clear that they still have full freedom to conclude the 232 investigations and to choose any policy measures as a result,' said another EU negotiator. While EU officials cannot predict the outcome of the US investigation, they believe it is nearing completion. 'These are two investigations—pharmaceuticals and semiconductors—that are pretty close to conclusion,' an official noted. If the US does impose tariffs following the investigation, the EU expects these to be capped at 15% for both sectors, in line with the political understanding reached during the trade talks. EU's bet on pharma tariffs The EU's strategy is clear: even though Trump could not legally commit yesterday to tariffs on pharmaceuticals while the investigation is ongoing, the EU insisted on a 15% ceiling across all sectors, with no exclusions for pharmaceuticals. A senior EU official added that this understanding is backed by a broader political commitment, including planned investments by pharmaceutical companies in the US and pressure from the industry on both sides of the Atlantic to collaborate more closely. 'There is a clear understanding that investments, supply chain integration, and joint R&D efforts should all fall under the special 15% regime,' the official explained. Still, the EU acknowledges that this is not yet a legally binding commitment. 'Is this a legal commitment? No, not at this stage. That would have to come through an executive order once the US concludes its investigation,' the source continued. For now, both pharmaceutical and semiconductor products remain at zero-duty 0rates. No changes will occur on 1 August, but that could change once the US finalises its Section 232 investigation.
Fashion Network
5 hours ago
- Fashion Network
Portugal's ISTO gets new backer, plans London store within a year
Portuguese fashion label ISTO has announced a strategic partnership with investment and operational firm Altaz Capital. Altaz, which was founded only this year, specialises in supply chain optimisation, operations, logistics, international expansion, and financial strategy, will support the firm's 'measured growth' based on its international expansion plan. That plan includes global growth including the aim of opening a store in London in the next eight-to-12 months. The partnership is effective immediately, with joint initiatives already under way to enhance the brand's operations and strengthen its financial foundations. The eight-year-old menswear label said the link-up 'marks a significant step' in its 'mission to build a globally recognised brand through steady, sustainable growth rather than rapid, unsustainable scale'. It added that both companies share a belief that 'doing the right thing takes time, hard work, and risk' and have come together to blend ISTO's 'commitment to timeless design made in Portugal and transparency with Altaz Capital's operational expertise and hands-on approach'. Brand co-founder and CEO Pedro Palha explained: 'As we thought about ISTO's next step we wanted to ensure we had the right expertise and partners who'd work alongside us daily. Altaz Capital is exactly that kind of partner. Their team brings a global background and connections, with a critical know-how in strategy, operations, and finance, which will help us strengthen our foundation and grow internationally at the right pace.' Lisbon-based ISTO has a belief in 'radical transparency, timeless product design, and 100% Portuguese production'. It said it's 'determined to scale without compromising its values, focusing on long-term relationships with suppliers, partners, and customers'. Altaz is known for working co-operatively with companies 'to implement solutions rather than just funding them', we're told and managing partner Sérgio Massano hailed ISTO's 'focus on product excellence and innovation'. He added that the partnership 'reflects our confidence in ISTO's team and our belief in the brand's potential for significant global expansion'. As part of the agreement, Massano joins Pedro Palha and Pedro Gaspar's leadership as a managing partner and André Flórido takes the role of CFO.
